Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Posters FSGS

Evaluating the Predictors of Structural Features in Kidney Biopsies from Adults with Focal Segmental Glomerulosclerosis

Learn More
Posters FSGS

Predictors of Progression toKidney Failure in Patients with Focal Segmental Glomerulosclerosis

Learn More
Posters FSGS

The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Focal Segmental Glomerulosclerosis (FSGS) and Immunoglobulin A Nephropathy (IgAN) on Patients and Caregivers Study (HONUS): Preliminary Results for IgAN in the United States (US)

Learn More
Posters FSGS

Long-Term Efficacy and Safety of Sparsentan in FSGS: 240-Week Analysis of the DUET Open-Label Extension

Learn More
Posters IgAN

Proteinuria and its association with disease progression in IgA nephropathy: Analysis of the UK national RaDaR IgA nephropathy cohort

Learn More
Posters IgAN

Proteinuria and its association with disease progression in IgA nephropathy: Analysis of the UK National RaDaR IgA nephropathy cohort

Learn More
Posters FSGS

Differentiating primary and secondary FSGS using non-invasive urine biomarkers

Learn More
Posters FSGS

Differentiating primary and secondary FSGS using non-invasive urine biomarkers

Learn More
Posters FSGS

Sparsentan Improves Glomerular Endothelial and Podocyte Functions and Augments Protective Tissue Repair in a Mouse Model of Focal Segmental Glomerulosclerosis (FSGS)

Learn More
Posters

Development of a Treatment Response Prediction Strategy for Sparsentan in Glomerular Disease

Learn More
Posters

Development of a Treatment Response Prediction Strategy for Sparsentan in Glomerular Disease

Learn More
Posters

Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: Open-label Drug-Drug Interaction Study in Healthy Adults

Learn More
Posters

Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: Open-label Drug-Drug Interaction Study in Healthy Adults

Learn More